By Mehak Najeeb — SCN News
STOCKHOLM — French chemist Henri B. Kagan and Japanese scientist Kenso Soai have won the 2026 Nobel Prize in Chemistry for discoveries that helped scientists control one of chemistry's most fundamental and medically important problems: why molecules that contain exactly the same atoms can exist as two mirror images yet behave very differently inside the human body. Their work gave chemists powerful methods for steering reactions toward a desired molecular form, helping lay the foundations for modern pharmaceutical manufacturing and allowing drug developers to produce medicines with far greater molecular precision.
The Royal Swedish Academy of Sciences announced the award in Stockholm on Wednesday, recognizing decades of work on asymmetric chemistry and the phenomenon known as chirality. Kagan, 95, and Soai, 76, will share the 12 million Swedish kronor prize, worth about $1.2 million, and are scheduled to receive their medals at the Nobel ceremony in Stockholm on December 10. Their recognition comes more than a century after scientists first began confronting the mystery of why nature so often chooses one molecular "hand" over its mirror image.
The chemistry problem is surprisingly simple to visualize
Hold out your two hands with the palms facing upward. They look almost identical, and each has the same basic components, but no matter how you rotate them, your left hand cannot be perfectly placed over your right hand. Chemistry contains molecules with essentially the same property: they can have the same atoms and chemical formula while existing in two structures that are mirror images of one another.
Chemists describe these molecules as chiral, a term derived from the Greek word for hand. Their two mirror forms are known as enantiomers, and although their chemical composition may appear identical on paper, their three-dimensional arrangement can determine how they interact with proteins, enzymes and receptors inside living organisms. Nobel educational material defines a chiral molecule as one that cannot be superimposed on its mirror image regardless of how it is rotated.
That difference can produce striking results even outside medicine. AP highlighted the molecule carvone: one mirror-image version is associated with the smell of mint, while its opposite form smells like caraway. Human biology itself displays the same selectivity — DNA twists in a particular direction and proteins are constructed primarily from one molecular handedness rather than an equal mixture of both.
In medicine, choosing the wrong molecular hand can matter enormously
The pharmaceutical implications are much more consequential than differences in smell. A drug molecule can fit into a biological receptor somewhat like a hand fits into a glove, meaning one molecular orientation may produce the desired therapeutic effect while its mirror image can be less effective, inactive or behave differently. Pharmaceutical chemists therefore need ways not simply to manufacture a compound, but to manufacture predominantly the correct three-dimensional version of that compound.
The Nobel Committee emphasized that this ability has become a foundational tool in drug development. Committee member Peter Somfai explained that the left-handed version of a drug can produce one effect while the right-handed version produces another, creating the need for techniques that selectively prepare the required form. Kagan and Soai supplied major pieces of the chemistry needed to achieve that control.
The historical stakes are often illustrated by thalidomide, the sedative associated with severe birth defects in thousands of children during the late 1950s and early 1960s. The chemistry surrounding thalidomide is more complicated than a simple claim that manufacturers could merely have removed one form, because the molecule can interconvert between forms under biological conditions. Nevertheless, the disaster became an enduring demonstration of why the three-dimensional behavior and biological effects of different molecular forms must be understood during drug development.
Kagan helped chemistry learn how to choose a side
Kagan's research was central to the development of asymmetric synthesis — chemical reactions designed to produce more of one molecular mirror image than the other. Instead of allowing a reaction to generate roughly equal quantities of both forms and then attempting to separate them afterward, asymmetric chemistry offered the possibility of directing the reaction itself toward the desired structure.
His work demonstrated that carefully designed catalysts could strongly favor one molecular orientation. That concept became enormously important because catalysts allow chemists to guide reactions without being consumed in the process, potentially making manufacturing more efficient while generating a much larger proportion of the molecular form required for a medicine or other specialized chemical.
Kagan's recognition is particularly notable because his contribution to asymmetric chemistry has been discussed in Nobel circles for decades. When the 2001 Nobel Prize in Chemistry recognized work in chirally catalysed reactions, Kagan was not among the three recipients despite the influence of his research, prompting criticism in France at the time. Twenty-five years later, at age 95, he has now received chemistry's highest honor for the broader scientific breakthrough to which his research contributed.
Then Soai demonstrated something chemistry had never seen before
Soai's contribution pushed the mirror-image problem into even more remarkable territory. His experiments produced what became known as the Soai reaction, an asymmetric autocatalytic reaction capable of strongly amplifying a tiny initial imbalance between molecular mirror images. In simple terms, once a slight preference for one molecular hand appeared, the chemistry could reinforce that preference as the reaction continued.
This provided scientists with an experimental route toward understanding how extremely small asymmetries might become amplified into overwhelming molecular preference. The discovery attracted attention beyond synthetic chemistry because it offered a potential chemical model for thinking about one of life's oldest mysteries: why biological systems overwhelmingly use particular molecular orientations instead of equal amounts of both.
AP reported that Nobel Committee members described Soai's work as an extraordinary organic chemistry experiment, while scientists emphasized that the wider discoveries gave researchers both practical manufacturing tools and deeper insight into molecular behavior. The implications consequently extend from pharmaceutical factories to fundamental questions about how the chemistry associated with life developed.
The mystery stretches back to Louis Pasteur
The intellectual path toward this year's Nobel began long before either laureate was born. In the 19th century, French scientist Louis Pasteur studied tartaric acid, a substance associated with winemaking, and discovered molecular forms that behaved differently despite apparently having the same chemical composition.
Pasteur observed that biological processes could distinguish between the two forms. His work established one of the earliest foundations of stereochemistry — the study of how atoms are arranged in three-dimensional space — and opened a question that would occupy chemists for generations: if two molecular structures are mirror images, why does nature so strongly prefer one over the other?
Kagan and Soai did not simply observe that preference. Their work helped demonstrate how chemists could create and amplify it deliberately, moving the science from recognizing molecular handedness toward controlling it.
Why this Nobel matters to modern medicine
The significance of the prize is not confined to a single blockbuster drug or one manufacturing process. The chemistry recognized Wednesday became part of the conceptual and technical toolkit used throughout modern pharmaceutical research, where scientists routinely need to understand and control stereochemistry when designing compounds.
American Chemical Society President Rigoberto Hernandez told AP that today's medicines would not be possible without this chemistry, while Nobel Committee members emphasized how broadly asymmetric methods influence contemporary drug development. That does not mean every medicine is directly manufactured using one specific Kagan or Soai reaction; rather, their discoveries transformed the scientific framework chemists use to design catalysts and control molecular handedness.
The same principles extend beyond pharmaceuticals. Chirality can matter in fragrances, agricultural chemicals, materials science and other industries because molecular orientation can alter how a substance interacts with its environment. A method capable of producing the required orientation selectively can reduce unwanted products and make sophisticated chemical synthesis more precise.
A Nobel spanning France and Japan — and generations of chemistry
The two laureates represent different generations and scientific traditions. Kagan, affiliated with Université Paris-Sud in Orsay, France, is 95, making him the third-oldest Nobel laureate at the time of receiving the award, according to Reuters. Soai, affiliated with Tokyo University of Science, is 76 and was out shopping when the Nobel Committee reached him with the news.
Soai described receiving the call as one of the most exciting moments of his life and said he was pleased to share the prize with Kagan. French President Emmanuel Macron also congratulated the laureates, describing Kagan's recognition as an immense honor for France after a lifetime devoted to scientific research.
The chemistry award is the third Nobel announced during the 2026 Nobel week, following the prizes in physiology or medicine and physics. Literature is due next, followed by the Nobel Peace Prize and then the economics award, while the formal Nobel ceremonies will take place on December 10, the anniversary of Alfred Nobel's death.
The numbers behind the 2026 Chemistry Nobel
The award brings together two scientists, two countries and decades of research around a molecular problem first recognized more than a century ago. Kagan is 95 and Soai 76, a 19-year age difference, while the prize fund totals 12 million Swedish kronor — approximately $1.2 million. The scientific path itself stretches back to Pasteur's 19th-century experiments, demonstrating the unusually long arc between recognizing molecular handedness and developing sophisticated methods capable of controlling it.
The more important number, however, cannot easily be counted: the vast range of chemical and pharmaceutical research that now depends on controlling molecules in three dimensions. What once appeared to be a subtle difference between two almost identical structures became essential knowledge for deciding whether a molecule interacts with biology in the way scientists intend.
That is why the 2026 Nobel Prize in Chemistry is ultimately about more than two mirror images. Kagan and Soai helped chemistry learn how to choose between them, providing researchers with tools to control molecular handedness rather than simply observe it. In pharmaceutical science, where microscopic structural differences can translate into dramatically different biological outcomes, that ability has become one of modern chemistry's most consequential achievements.